Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaBladder CancerBreast CancerHepatocellular CarcinomaLung Carcinoma, Non-Small CellLung Carcinoma, Small CellPancreatic CancerTumor, Various OrgansTumor Biomarker DefinedSubgroupNRG1-Fusiontripel negativeICD10C22.0C24.-C24.0C24.1C24.8C24.9C25.-C34.-C50.-C67.-MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungCarcinoma, Transitional CellCommon Bile Duct NeoplasmsLiver NeoplasmsNeoplasmsPancreatic NeoplasmsSmall Cell Lung CarcinomaUrinary Bladder NeoplasmsSequenceChemotherapyChemo-substanceAtezolizumabCisplatinHydrocortisoneThiotepaZenocutuzumab Chemo-substanceAtezolizumabCisplatinHydrocortisoneThiotepaZenocutuzumab Chemo-substanceAtezolizumabCisplatinHydrocortisoneThiotepaZenocutuzumab Chemo-substanceAtezolizumabCisplatinHydrocortisoneThiotepaZenocutuzumab No. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolNo. Substances4Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentioncurative or palliativepalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)HyperglycemiaIncrease AminotransferasesInfusion ReactionNauseaVomiting only studiesPublicationAuthorBurotto MMaisch BMartinoni A Schram AMDiseaseMaligner Perikarderguss, hämodynamisch relevantNSCLC, lokal fortgeschritten oder metastasiert, ECOG 0-1Tumore unterschiedlicher Lokalisation, lokal fortgeschritten oder metastasiert, NRG1-Fusion, Zweitlinie, ECOG 0-2OriginCardiology Unit, Milan, ItalyCentro de Investigacion, Clinica Bradford Hill, Santiago, Chile, IMscin001 trialDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, eNRGy trialProtocols in Revision 4 protocols foundAtezolizumab 1875, single dose subcutaneous (PID3181 V1.0)Cisplatin 30, Tumor, Various Organs (PID2371 V1.0)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372 V1.0)Zenocutuzumab 750, Tumor Biomarker Defined (PID3015 V1.0)
